RBX7455 Before Surgery for the Treatment of Operable Breast Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

January 11, 2023

Study Completion Date

January 11, 2023

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Breast AdenocarcinomaInvasive Breast CarcinomaPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Triple-Negative Breast Carcinoma
Interventions
DRUG

Microbiota-based Formulation RBX7455

Given PO

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04139993 - RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | Biotech Hunter | Biotech Hunter